Keywords
Migalastat
kidney disease
globotriasylceramide
rare diseases
case report
How to Cite
Abstract
Introduction: Fabry disease, or Anderson-Fabry disease, is a lysosomal deposition disease caused by deficiency or absence of the enzyme ?-galactosidase A, which is responsible for the catabolism of the glycosphingolipid globotriaosylceramide (Gb3).
Purpose: This article reports the case of a patient who, at the age of 64 years with a diagnosis of Fabry disease, begins treatment with the new oral chaperone (migalastat), with evidence of improvement in his natural history of the disease.
Case presentation: A 64-year-old male patient, native of Porto-Portugal, resident in Medellin-Colombia, with Fabry disease diagnosed in 2010, due to Alpha Galactosidase A activity plus phenotyping mutation C.239G>A.
Discussion and conclusions: This case report has shown the adequate response of the patient in management with the pharmacological chaperone migalastat. Therefore, a patient with Fabry disease, with typical manifestations and a confirmed GLA mutation and who is susceptible to migalastat, has this excellent therapeutic option with favorable results for his signs and symptoms.
Migalastat (pharmacological chaperone) is an effective and safe oral treatment which translates into comfort and benefits for the patient and his environment, and this allows a significant improvement in the patient's quality of life.
References
Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5(30):1-49. https://doi.org/10.1186/1750-1172-5-30
Tomsen J, Passemard S, García N, Díaz ZV, González R, Nedergaard J, et al. Impact of Chemical Composition on the Nanostructure and Biological Activity of ?-Galactosidase-Loaded Nanovesicles for Fabry Disease Treatment. ACS Appl Mater Inter. 2021;13(7):7825-38. https://doi.org/10.1021/acsami.0c16871
MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750-60. https://doi.org/10.1136/jmg.38.11.750
Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008;130(3):367-73. https://doi.org/10.1016/j.ijcard.2008.03.007
Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart, A, Nicholls K, et al. Cardiovascular events in patients with Fabry disease: natural history data from the Fabry Registry. J Am Coll Cardiol. 2011;57(9):1093-9. https://doi.org/10.1016/j.jacc.2010.11.018
Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24(7):2102-11. https://doi.org/10.1093/ndt/gfp031
Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11(11):790-6. https://doi.org/10.1097/gim.0b013e3181bb05bb
Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353-8. https://doi.org/10.1136/jmedgenet-2014-102797
Germain DP, Giugliani R, Bichet DG, Wilcox WR, Hughes DA, Amartino HM, et al. Efficacy of migalastat in a cohort of male patient with classic Fabry phenotype in the FACETS phase 3 study (abstract no. 102). Mol Genet Metab. 2017;120(1-2):S52. https://doi.org/10.1016/j.ymgme.2016.11.111
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.